MindScan will enable faster and more accurate diagnosis of neuropsychiatric disorders to improve patient outcomes and clinical research

Doctor patient.png

Challenges

Neuropsychiatric disorders such as ADHD, Bipolar Disorder, Schizophrenia and Depression result in significant medical disability and healthcare costs. The absence of accurate, valid, and objective tools leads to delayed and inaccurate diagnoses contributing to poor patient outcomes and unnecessary healthcare costs.

Neuropsychiatric clinical research is complex, expensive and has significant risks. Recruiting patients and measuring efficacy solely based on subjective criteria and assessments can lead to missed endpoints and trial failure.

Clinical Research

Even at leading academic centers neuropsychiatric clinical study recruitment is very difficult due to reliance on subjective diagnostic criteria and lack of valid, objective tools with proven accuracy.

Exclusive reliance on subjective efficacy measurements can lead to missed endpoints and clinical study failure. Failed trials may undermine future investments in neuropsychiatric research and development.

Clinical Practice

Timely and accurate diagnosis of neuropsychiatric disorders is challenging due to:

  • Complexities of the conditions and symptom overlap

  • Variable levels of training and time constraints

  • Lack of valid, objective tools with proven accuracy

Sole reliance on subjective judgments can lead to misdiagnoses, incorrect therapies and delayed time to appropriate treatment.

Our Approach

Partnerships to Improve Clinical Research

MindScan’s technology will allow neuropsychiatric R&D programs to improve the accuracy and efficiency of clinical study recruitment and efficacy measurement.

Clinical studies can supplement subjective evaluations with accurate classification reports to recruit patients for clinical trials. Patients can also be recruited directly from MindScan’s opt-in database.

MindScan will also partner with pharmaceutical companies to supplement subjective evaluations of efficacy with objective measurements. These measurements are based on changes in brain morphology indicative of drug response, such as changes in cortical thickness in specific regions of the brain.

 These partnerships will enable more precise and efficient neuropsychiatric disorder R&D for conditions such as ADHD, Bipolar Disorder, Schizophrenia, and Depression. They will also increase the probability of clinical trial success and encourage further investment in neuropsychiatric disorder research and development.

Classification Reports to Improve Diagnostic Accuracy

MindScan’s technology will enable physicians to significantly improve neuropsychiatric disorder diagnostic accuracy and support earlier, more effective treatment.  

Physicians will be able to order classification reports for ADHD, Bipolar Disorder, and Schizophrenia shown to have high sensitivity (93.6% to 100%) and high specificity (88.5% to 100%) versus gold-standard, consensus panels of experts using research-grade clinical data. Sensitivity is the ability to correctly identify a person as having the condition.  Specificity is the ability to correctly identify a person as not having a condition. These classification reports will allow physicians to increase the speed and accuracy of their diagnoses.

To develop these reports, MindScan uploads anatomical MRI brain scans via a SaaS cloud platform. MindScan defines regions of interest and applies its proprietary machine learning derived algorithm.

 This algorithm detects neural “fingerprints” indicative of the presence or absence of specific neuropsychiatric disorders, including ADHD, Bipolar Disorder, Schizophrenia, and Depression. MindScan then matches each patient’s neural “fingerprint” to a proprietary database. Based on this analysis, MindScan develops classification reports and send them to physicians to inform their diagnoses. 

About Us

Eric Sandquist, CEO and co-founder, will leverage his healthcare general management and startup experience to ensure success. Co-founder Bradley Peterson, MD, an internationally known imaging expert, neuroscientist, and child psychiatrist, will provide scientific leadership and support adoption. Co-founder Ravi Bansal, PhD, a leading imaging and computer scientist, will provide scientific and engineering leadership.